TRIM6 promotes glioma malignant progression by enhancing FOXO3A ubiquitination and degradation.

IF 4.5 2区 医学 Q1 ONCOLOGY
Translational Oncology Pub Date : 2024-08-01 Epub Date: 2024-05-17 DOI:10.1016/j.tranon.2024.101999
Jingpeng Guo, Ji Wang, Peng Zhang, Ping Wen, Shoudan Zhang, Xuchen Dong, Jun Dong
{"title":"TRIM6 promotes glioma malignant progression by enhancing FOXO3A ubiquitination and degradation.","authors":"Jingpeng Guo, Ji Wang, Peng Zhang, Ping Wen, Shoudan Zhang, Xuchen Dong, Jun Dong","doi":"10.1016/j.tranon.2024.101999","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>TRIM6, an E3 ubiquitin ligase with tripartite motif, directly targets protein substrates for degradation through ubiquitination. Studies have shown that TRIM6 plays a significant role in tumor development in various human malignancies. Thus, the aim of this study was to investigate the importance of TRIM6 and its associated mechanism in promoting the progression of glioma.</p><p><strong>Methods: </strong>The expression of TRIM6 and its prognostic value in glioma patients were collected from the TCGA and CGGA databases. The effects of TRIM6 on glioma were investigated in vitro by CCK8, colony formation, wound healing, and transwell assays. Co-IP and western blot analysis were used to detect the interaction between TRIM6 and FOXO3A. The effects of TRIM6 were verified in vivo in subcutaneously xenograft models, and tumor size, and immunohistochemical changes were observed.</p><p><strong>Results: </strong>Our analysis of TRIM6 expression in glioma tissues revealed a high level of expression, and the heightened expression of TRIM6 showed a positive correlation with the unfavorable prognosis among glioma/GBM patients. Through loss-of-function and gain-of-function experiments, we observed a profound impact on the proliferation, invasion, and migration abilities of glioma cells both in vitro and in vivo upon deletion of TRIM6. Conversely, the overexpression of TRIM6 intensified the malignant characteristics of glioma. Additionally, our findings revealed a significant interaction between TRIM6 and FOXO3A, wherein TRIM6 contributed to the destabilization of FOXO3A protein by promoting its ubiquitination and subsequent degradation. Experiments conducted in the rescue study affirmed that the promotion of glioma cell proliferation, invasion, and migration is facilitated by TRIM6 through the suppression of FOXO3A protein levels.</p><p><strong>Conclusions: </strong>These observations imply that the TRIM6-FOXO3A axis could potentially serve as an innovative focus for intervening in glioma.</p>","PeriodicalId":23244,"journal":{"name":"Translational Oncology","volume":null,"pages":null},"PeriodicalIF":4.5000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11127279/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.tranon.2024.101999","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/17 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: TRIM6, an E3 ubiquitin ligase with tripartite motif, directly targets protein substrates for degradation through ubiquitination. Studies have shown that TRIM6 plays a significant role in tumor development in various human malignancies. Thus, the aim of this study was to investigate the importance of TRIM6 and its associated mechanism in promoting the progression of glioma.

Methods: The expression of TRIM6 and its prognostic value in glioma patients were collected from the TCGA and CGGA databases. The effects of TRIM6 on glioma were investigated in vitro by CCK8, colony formation, wound healing, and transwell assays. Co-IP and western blot analysis were used to detect the interaction between TRIM6 and FOXO3A. The effects of TRIM6 were verified in vivo in subcutaneously xenograft models, and tumor size, and immunohistochemical changes were observed.

Results: Our analysis of TRIM6 expression in glioma tissues revealed a high level of expression, and the heightened expression of TRIM6 showed a positive correlation with the unfavorable prognosis among glioma/GBM patients. Through loss-of-function and gain-of-function experiments, we observed a profound impact on the proliferation, invasion, and migration abilities of glioma cells both in vitro and in vivo upon deletion of TRIM6. Conversely, the overexpression of TRIM6 intensified the malignant characteristics of glioma. Additionally, our findings revealed a significant interaction between TRIM6 and FOXO3A, wherein TRIM6 contributed to the destabilization of FOXO3A protein by promoting its ubiquitination and subsequent degradation. Experiments conducted in the rescue study affirmed that the promotion of glioma cell proliferation, invasion, and migration is facilitated by TRIM6 through the suppression of FOXO3A protein levels.

Conclusions: These observations imply that the TRIM6-FOXO3A axis could potentially serve as an innovative focus for intervening in glioma.

TRIM6 通过增强 FOXO3A 泛素化和降解促进胶质瘤恶性进展。
目的:TRIM6 是一种具有三方基序的 E3 泛素连接酶,通过泛素化直接靶向蛋白质底物进行降解。研究表明,TRIM6 在多种人类恶性肿瘤的发展过程中发挥着重要作用。因此,本研究旨在探讨TRIM6及其相关机制在促进胶质瘤进展中的重要性:方法:从TCGA和CGGA数据库中收集胶质瘤患者中TRIM6的表达及其预后价值。在体外通过CCK8、集落形成、伤口愈合和透孔试验研究了TRIM6对胶质瘤的影响。研究人员使用 Co-IP 和 Western 印迹分析检测 TRIM6 与 FOXO3A 之间的相互作用。在体内皮下异种移植模型中验证了 TRIM6 的作用,并观察了肿瘤大小和免疫组化变化:结果:我们对胶质瘤组织中 TRIM6 的表达进行了分析,发现其表达水平很高,而且 TRIM6 的高表达与胶质瘤/GBM 患者的不良预后呈正相关。通过功能缺失和功能增益实验,我们观察到缺失 TRIM6 后,胶质瘤细胞在体外和体内的增殖、侵袭和迁移能力都会受到严重影响。相反,TRIM6 的过表达会增强胶质瘤的恶性特征。此外,我们的研究结果表明,TRIM6 和 FOXO3A 之间存在显著的相互作用,TRIM6 通过促进 FOXO3A 蛋白的泛素化和随后的降解来破坏其稳定性。救援研究中进行的实验证实,TRIM6 通过抑制 FOXO3A 蛋白水平,促进了胶质瘤细胞的增殖、侵袭和迁移:这些观察结果表明,TRIM6-FOXO3A 轴有可能成为干预胶质瘤的创新焦点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Translational Oncology
Translational Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research
CiteScore
7.20
自引率
2.00%
发文量
314
审稿时长
6-12 weeks
期刊介绍: Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信